Objective At present, there are few reports about the relationship between Chemerin and the occurrence and development of breast cancer. The aim of this study is to investigate Chemerin expression in breast cancer mice and its effect on proliferation and migration of breast cancer cells. Methods 30 Balb/c mice were randomly divided into two groups (Normal mice 15, Tumor-bearing mice 15). The 4T1 breast cancer cells were inoculated to construct breast cancer mice model. The expressions of Chemerin in peripheral blood and breast cancer tissue were detected by ELISA and Western blot, respectively. The relationship between Chemerin expression and breast cancer was analyzed. Breast cancer cells MCF-7 and MDA-MB-231 were treated with different concentrations of recombinant Chemerin protein and Chemerin neutralizing antibody. Three groups were set up in the experiment, including control group (1640 or DMEM culture medium, no cells), recombinant Chemerin protein group (100 μg/L, no dilution by serum-free medium) and Chemerin neutralizing antibody group (100 μg/L, no dilution by serum-free medium). The effects of Chemerin on cell proliferation and migration were detected by MTT assay and wound healing assay respectively. Results The expressions of Chemerin in peripheral blood and mammary gland of tumor bearing mice were significantly higher than that in normal mice (both P<0.05). The scratch mobility and MTT absorbance (OD) values of breast cancer cells treated with recombinant chemerin protein increased significantly with the increase of protein concentration (P<0.05).However, they significantly decreased after cells treated with chemerin neutralizing antibody (P<0.05). Conclusion Chemerin could promote the proliferation and migration of breast cancer cells in a concentration-dependent manner, thereby promotinge the occurrence and development of breast cancer.

OBJECTIVETo investigate the application of partial costectomy and costophrenic angle closure (PCCAC) and perioperative management in the treatment of liver tumor by high intensity focused ultrasound (HIFU).

METHODSThe clinical data of 69 patients with liver tumor underwent HIFU within the recent four years were retrospectively reviewed.

RESULTS92.8% of these 69 liver tumor patients had had concomitant diseases and 13.0% of them developed postoperative complications without anyone died. There was no significant postoperative dysfunctions of kidney or lung as compared with the preoperative ones (P > 0.05).

CONCLUSIONIn the treatment of liver tumor by HIFU, PCCAC, as an auxillary means, giving few complications and little harmful effects on respiratory physiology, is highly safe.

Adult ; Aged ; Carcinoma, Hepatocellular ; therapy ; Female ; Humans ; Liver Neoplasms ; therapy ; Male ; Middle Aged ; Retrospective Studies ; Ribs ; surgery ; Treatment Outcome ; Ultrasound, High-Intensity Focused, Transrectal